The Filing Desk

Bionano Genomics vs Alpha Teknova

Bionano Genomics BNGO · Alpha Teknova TKNO · Life Sciences Tools & Services

Alpha Teknova reported revenue of $40 million in fiscal 2025, 1.4 times Bionano Genomics' $28 million in fiscal 2025. Bionano Genomics' revenue fell 7.4% in its latest year, and Alpha Teknova's grew 7.3%. Bionano Genomics had an operating margin of -117.0%, against -41.9% at Alpha Teknova. Free cash flow was −$16 million at Bionano Genomics and −$10 million at Alpha Teknova.

Side by side

Bionano GenomicsAlpha Teknova
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$28M$40M
Revenue growth−7.4%7.3%
Revenue growth a year, last 5 years27.4%5.3%
Gross margin46.2%33.2%
Operating margin−117.0%−41.9%
Net margin−92.6%−42.6%
Free cash flow−$16M−$10M
Free cash flow margin−57.3%−24.2%
Return on capital−89.9%−22.0%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count328.4%14.4%
Last close$0.89$7.81
P/E at the last close——
Insider trades, last 12 months—bought $143,500, sold $0
Piotroski F-score5 of 95 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Bionano GenomicsAlpha Teknova
Operating margin
Percent of revenue
Bionano GenomicsAlpha Teknova
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Bionano GenomicsAlpha Teknova

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Bionano Genomics and Alpha Teknova pages.